fluorouracil has been researched along with Weight Gain in 25 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse." | 7.67 | Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. ( Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989) |
| "Weight gain is a common side effect observed in women undergoing adjuvant chemotherapy for breast cancer." | 6.70 | Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body composition. ( Banzi, MC; Bertolini, M; Bondi, M; Del Rio, G; Federico, M; Menozzi, R; Piccinini, L; Valeriani, L; Zironi, S, 2002) |
| "The ADEBAR trial compares a sequential chemotherapy consisting of epirubicin/cyclophosphamide followed by docetaxel to an epirubicin/5-fluorouracil/cyclophosphamide regimen in patients with lymph node-positive early breast cancer." | 5.27 | Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. ( Beckmann, MW; de Gregorio, N; Fasching, PA; Fehm, T; Friedl, TWP; Harbeck, N; Jäger, B; Janni, W; Jückstock, J; Mahner, S; Mohrmann, S; Mutschler, NS; Rack, B; Salmen, J; Schochter, F; Scholz, C; Weissenbacher, T; Widschwendter, P; Ziegler, C; Zwingers, T, 2018) |
| "This prospective phase II clinical trial was performed to explore the activity and efficacy of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric adenocarcinoma." | 5.09 | Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. ( Aragao, BC; Cabral, LO; Guimaraes, RC; Murad, AM; Petroianu, A; Scalabrini-Neto, AO, 1999) |
| "The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse." | 3.67 | Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. ( Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989) |
| "Pentoxifylline (PTX) is a drug that has been shown to have multiple beneficial effects in cancer patients through its anti-inflammatory properties." | 3.01 | Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2021) |
| " We have previously demonstrated that by means of a comprehensive dietary modification which aims at lowering insulin levels it is possible to reduce body weight and decrease the bioavailability of insulin, sex hormones and the growth factors linked to BC risk and prognosis." | 2.77 | Preventing weight gain during adjuvant chemotherapy for breast cancer: a dietary intervention study. ( Berrino, F; Bruno, E; Curtosi, P; Evangelista, A; Gargano, G; Morelli, D; Pasanisi, P; Raimondi, M; Villarini, A, 2012) |
| "Fifty-five (55) patients with renal cell cancer were randomly divided into a Haishengsu group (n = 27, 2." | 2.74 | Effect of haishengsu as an adjunct therapy for patients with advanced renal cell cancer: a randomized and placebo-controlled clinical trial. ( Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B; Zhao, XW, 2009) |
| "Weight gain was observed in 12 of 33 (36%) patients." | 2.71 | Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. ( Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N, 2004) |
| "Weight gain is a common side effect observed in women undergoing adjuvant chemotherapy for breast cancer." | 2.70 | Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body composition. ( Banzi, MC; Bertolini, M; Bondi, M; Del Rio, G; Federico, M; Menozzi, R; Piccinini, L; Valeriani, L; Zironi, S, 2002) |
| "Weight gain was observed in 48% of patients, and dysphagia improved in 76%." | 2.70 | Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. ( Artru, P; Baujat, B; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Maindrault, F; Taïeb, J; Tournigand, C, 2002) |
| "Nurses can inform women with breast cancer about the expected changes in body weight after chemotherapy to reduce their uncertainty." | 1.40 | Weight change trajectory in women with breast cancer receiving chemotherapy and the effect of different regimens. ( Chen, ML; Jeng, C; Lin, YC; Liu, LN; Miaskowski, C; Wang, JS; Wen, FH, 2014) |
| "Weight gain was noted in the treatment groups compared with the gel base and control groups (P < ." | 1.39 | Healing acceleration in hamsters of oral mucositis induced by 5-fluorouracil with topical Calendula officinalis. ( Amanat, D; Garcia-Godoy, F; Saghiri, MA; Samani, SM; Tadbir, AA; Tamadon, A; Tanideh, N; Tavakoli, P, 2013) |
| "5-Fluorouracil (5-FU) is a cytostatic drug associated with chemotherapy-induced cognitive impairments that many cancer patients experience after treatment." | 1.38 | Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. ( Bennett, G; ElBeltagy, M; Lyons, L; Wigmore, P, 2012) |
| "Weight gain is reported as a common finding in patients treated for breast cancer but its aetiology appears to be complex." | 1.31 | Weight gain during adjuvant and neoadjuvant chemotherapy for breast cancer: an audit of 100 women receiving FEC or CMF chemotherapy. ( Lankester, KJ; Lawton, PA; Phillips, JE, 2002) |
| "Weight gain is a reported problem associated with adjuvant chemotherapy for breast cancer and often generates psychosocial stress in women [1]." | 1.30 | Changes in body composition during breast cancer chemotherapy with the CMF-regimen. ( Allen, BJ; Aslani, A; Levi, JA; Pavlakis, N; Smith, RC, 1999) |
| "Weight gain was correlated positively with several psychologic measures but not with assessed biologic measures." | 1.28 | Weight gain with breast cancer adjuvant treatment. ( Carpenter, JT; Levine, EG; Raczynski, JM, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meirovitz, A | 1 |
| Baider, L | 1 |
| Peretz, T | 1 |
| Stephanos, S | 1 |
| Barak, V | 1 |
| Mutschler, NS | 1 |
| Scholz, C | 1 |
| Friedl, TWP | 1 |
| Zwingers, T | 1 |
| Fasching, PA | 1 |
| Beckmann, MW | 1 |
| Fehm, T | 1 |
| Mohrmann, S | 1 |
| Salmen, J | 1 |
| Ziegler, C | 1 |
| Jäger, B | 1 |
| Widschwendter, P | 1 |
| de Gregorio, N | 1 |
| Schochter, F | 1 |
| Mahner, S | 1 |
| Harbeck, N | 1 |
| Weissenbacher, T | 1 |
| Jückstock, J | 1 |
| Janni, W | 1 |
| Rack, B | 1 |
| Liu, LN | 1 |
| Wen, FH | 1 |
| Miaskowski, C | 1 |
| Lin, YC | 1 |
| Wang, JS | 1 |
| Jeng, C | 1 |
| Chen, ML | 1 |
| Mustafa, S | 1 |
| Walker, A | 1 |
| Bennett, G | 2 |
| Wigmore, PM | 1 |
| Albertsson, P | 2 |
| Lennernäs, B | 2 |
| Norrby, K | 2 |
| Liu, JZ | 1 |
| Chen, SG | 1 |
| Zhang, B | 1 |
| Wang, CB | 1 |
| Zhao, XW | 1 |
| Li, GY | 1 |
| Wang, LX | 1 |
| Gordon, AM | 1 |
| Hurwitz, S | 1 |
| Shapiro, CL | 1 |
| LeBoff, MS | 1 |
| Bonatto, SJ | 1 |
| Oliveira, HH | 1 |
| Nunes, EA | 1 |
| Pequito, D | 1 |
| Iagher, F | 1 |
| Coelho, I | 1 |
| Naliwaiko, K | 1 |
| Kryczyk, M | 1 |
| Brito, GA | 1 |
| Repka, J | 1 |
| Sabóia, LV | 1 |
| Fukujima, G | 1 |
| Calder, PC | 1 |
| Fernandes, LC | 1 |
| Lyons, L | 1 |
| ElBeltagy, M | 1 |
| Wigmore, P | 1 |
| Villarini, A | 1 |
| Pasanisi, P | 1 |
| Raimondi, M | 1 |
| Gargano, G | 1 |
| Bruno, E | 1 |
| Morelli, D | 1 |
| Evangelista, A | 1 |
| Curtosi, P | 1 |
| Berrino, F | 1 |
| Tanideh, N | 1 |
| Tavakoli, P | 1 |
| Saghiri, MA | 1 |
| Garcia-Godoy, F | 1 |
| Amanat, D | 1 |
| Tadbir, AA | 1 |
| Samani, SM | 1 |
| Tamadon, A | 1 |
| Del Rio, G | 1 |
| Zironi, S | 1 |
| Valeriani, L | 1 |
| Menozzi, R | 1 |
| Bondi, M | 1 |
| Bertolini, M | 1 |
| Piccinini, L | 1 |
| Banzi, MC | 1 |
| Federico, M | 1 |
| Louvet, C | 2 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 2 |
| Beerblock, K | 1 |
| Vaillant, JC | 1 |
| Cady, J | 1 |
| André, T | 1 |
| Gamelin, E | 1 |
| de Gramont, A | 2 |
| Lennernäs, H | 1 |
| Stathopoulos, GP | 1 |
| Syrigos, K | 1 |
| Polyzos, A | 1 |
| Fountzilas, G | 1 |
| Rigatos, SK | 1 |
| Ziras, N | 1 |
| Potamiannou, A | 1 |
| Tsiakopoulos, I | 1 |
| Androulakis, N | 1 |
| Aravantinos, G | 1 |
| Athanasiadis, A | 1 |
| Papakotoulas, P | 1 |
| Georgoulias, V | 1 |
| Kumar, N | 1 |
| Allen, KA | 1 |
| Riccardi, D | 1 |
| Bercu, BB | 1 |
| Cantor, A | 1 |
| Minton, S | 1 |
| Balducci, L | 1 |
| Jacobsen, PB | 1 |
| Forshaw, MJ | 1 |
| Gossage, JA | 1 |
| Chrystal, K | 1 |
| Cheong, K | 1 |
| Harper, PG | 1 |
| Mason, RC | 1 |
| Neubauer, BL | 1 |
| Best, KL | 1 |
| Counts, DF | 1 |
| Goode, RL | 1 |
| Hoover, DM | 1 |
| Jones, CD | 1 |
| Sarosdy, MF | 1 |
| Shaar, CJ | 1 |
| Tanzer, LR | 1 |
| Merriman, RL | 1 |
| Murad, AM | 1 |
| Petroianu, A | 1 |
| Guimaraes, RC | 1 |
| Aragao, BC | 1 |
| Cabral, LO | 1 |
| Scalabrini-Neto, AO | 1 |
| Aslani, A | 1 |
| Smith, RC | 1 |
| Allen, BJ | 1 |
| Pavlakis, N | 1 |
| Levi, JA | 1 |
| Lankester, KJ | 1 |
| Phillips, JE | 1 |
| Lawton, PA | 1 |
| Taïeb, J | 1 |
| Artru, P | 1 |
| Baujat, B | 1 |
| Carola, E | 1 |
| Maindrault, F | 1 |
| Tournigand, C | 1 |
| Krulik, M | 1 |
| Levine, EG | 1 |
| Raczynski, JM | 1 |
| Carpenter, JT | 1 |
| Camoriano, JK | 1 |
| Loprinzi, CL | 1 |
| Ingle, JN | 1 |
| Therneau, TM | 1 |
| Krook, JE | 1 |
| Veeder, MH | 1 |
| Ishikawa, T | 1 |
| Tanaka, Y | 1 |
| Ishitsuka, H | 1 |
| Ohkawa, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| The Impact of a Moderate CAlorie and Protein REstriction PROgram (CARE-PRO) as an Efficient and Affordable Therapeutic Strategy in Patients With Barrett's Esophagus.[NCT03813381] | 160 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Effect of Combined Training Post-treatment Intervention in Lean Body Mass Recovery in Breast Cancer Survival. A Randomised Controlled Trial.[NCT01843608] | 90 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | |||
| Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441] | 204 participants (Anticipated) | Observational | 2014-05-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 trials available for fluorouracil and Weight Gain
| Article | Year |
|---|---|
Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I).
Topics: Aged; Antineoplastic Agents; Cachexia; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; | 2021 |
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuv | 2018 |
Effect of haishengsu as an adjunct therapy for patients with advanced renal cell cancer: a randomized and placebo-controlled clinical trial.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arcidae; C | 2009 |
Fish oil supplementation improves neutrophil function during cancer chemotherapy.
Topics: Antineoplastic Agents; Brazil; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fe | 2012 |
Preventing weight gain during adjuvant chemotherapy for breast cancer: a dietary intervention study.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, | 2012 |
Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body composition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Breast Neoplasms; Chemotherapy, Ad | 2002 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; D | 2004 |
Symptomatic responses to neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: are they worth measuring?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2006 |
Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analgesics; Antimetabolites, Antineoplastic; Antineoplastic | 1999 |
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2002 |
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1990 |
14 other studies available for fluorouracil and Weight Gain
| Article | Year |
|---|---|
Weight change trajectory in women with breast cancer receiving chemotherapy and the effect of different regimens.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2014 |
5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus.
Topics: Animals; Antimetabolites, Antineoplastic; Brain-Derived Neurotrophic Factor; Cell Count; Cell Prolif | 2008 |
Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Dose-Response Relationship, Drug; Endo | 2009 |
Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Brea | 2011 |
Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery.
Topics: Animals; Antidepressive Agents, Second-Generation; Antimetabolites, Antineoplastic; Body Weight; Bro | 2012 |
Healing acceleration in hamsters of oral mucositis induced by 5-fluorouracil with topical Calendula officinalis.
Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Calendula; Carboxymethylcellulose Sodium; Criceti | 2013 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
Chemotherapy and antiangiogenesis--drug-specific, dose-related effects.
Topics: Animals; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxor | 2003 |
Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit?
Topics: Adult; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 2004 |
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Topics: Adenocarcinoma; Adrenal Glands; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Dis | 1995 |
Changes in body composition during breast cancer chemotherapy with the CMF-regimen.
Topics: Adult; Aged; Anthropometry; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Breast | 1999 |
Weight gain during adjuvant and neoadjuvant chemotherapy for breast cancer: an audit of 100 women receiving FEC or CMF chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2002 |
Weight gain with breast cancer adjuvant treatment.
Topics: Adaptation, Psychological; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1991 |
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Colonic Neoplasms; Combined Modality Th | 1989 |